Referred to the House Committee on Energy and Commerce.
This bill prohibits the HHS Secretary from declaring or using a public health emergency authority with respect to abortion and terminates any such declaration in effect. It restores and mandates an in-person dispensing requirement for abortion drugs under the FDA risk evaluation and mitigation strategy (REMS), forbids FDA/HHS from exercising enforcement discretion or waiving that requirement, and conditions any REMS changes on every State submitting standardized abortion surveillance data to the CDC with specified variables.
Progressives emphasize access and privacy harms
Highly salient and partisan content may pass a chamber aligned with its policy priorities, but would be divisive and face opposition.
This bill prohibits the HHS Secretary from declaring or using a public health emergency authority with respect to abortion and terminates any such declaration in effect.
It restores and mandates an in-person dispensing requirement for abortion drugs under the FDA risk evaluation and mitigation strategy (REMS), forbids FDA/HHS from exercising enforcement discretion or waiving that requirement, and conditions any REMS changes on every State submitting standardized abortion surveillance data to the CDC with specified variables.
The bill defines key terms including abortion, abortion drug, certified health care provider, and unborn child (beginning at fertilization).
Narrow but highly contentious bill that restricts executive agency authority; plausible in a favorable chamber but faces steep Senate and legal hurdles.
How solid the drafting looks.
Progressives emphasize access and privacy harms
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize access and privacy harms
Likely views the bill as a substantive restriction on medication abortion access and an unnecessary intrusion on medical decision-making.
Sees the public-health-emergency prohibition and reinstated in-person REMS as rollback of telehealth access and as politicizing FDA authority.
Tends to see both safety and access tradeoffs.
Would appreciate clarity and data collection but worry about federal overreach, privacy, and potential unintended access barriers.
Likely seeks modest adjustments rather than outright rejection.
Likely supportive because the bill restricts chemical abortion availability, prevents emergency relaxations, and strengthens supervisory requirements for abortion drugs.
Views data mandates as accountability and safety measures.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow but highly contentious bill that restricts executive agency authority; plausible in a favorable chamber but faces steep Senate and legal hurdles.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize access and privacy harms
Narrow but highly contentious bill that restricts executive agency authority; plausible in a favorable chamber but faces steep Senate and l…
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for Protecting Life from Chemical Abortions Act.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.